Unable to attend this year’s

ECCO Congress 2016?

View the full-length webcasts of 2 Takeda-sponsored symposia

Management
of Ulcerative
Colitis

Putting Patients
at the Center

Friday, 18 March 2016
18:05 - 19:05

Plenary Hall
RAI Amsterdam
The Netherlands

Welcome From the Chair

Iris Dotan, MD

CHAIR
Tel Aviv Sourasky Medical Center
Tel Aviv, Israel


I am delighted to welcome you to one of two Takeda-organized satellite symposia at ECCO 2016: Management of Ulcerative Colitis: Putting Patients at the Center.

Unanticipated flare-ups are one of the most important unmet needs in patients with moderate–severe ulcerative colitis (UC) and significantly disrupt patients' health-related quality of life. Safety/tolerability of medical therapy is another key patient concern. This symposium will discuss patient-centric approaches that may potentially address these unmet needs and optimize clinical outcomes with the use of biologics. (Discussion of biologics for the treatment of Crohn's disease will take place at a second satellite symposium early tomorrow morning [Saturday, 19 March, 07:15–08:15; Plenary Hall, RAI Amsterdam]).

Peter Irving, MD, will discuss evolving treatment goals and desired patient outcomes. To help patients achieve long-term full disease control, Dr Irving will discuss the importance of educating patients on timely recognition of flare-up symptoms, and the difference between disease control perceived by patients (symptom relief) and measured objectively by endoscopy (mucosal healing). He will also focus on issues of suboptimal efficacy and safety/tolerability with medical therapy. Shared decision-making between physicians and patients on choosing a therapy with a favorable benefit–risk profile is the key first step to tackling these issues.

A recently proposed "treat-to-target" strategy responds to patients' needs, and helps physicians and patients achieve goals. This strategy requires close monitoring of patients for disease response or progression, and use of objective information to guide discussions and shared treatment decisions. David Rubin, MD, will review when and how to use conventional and biological therapies, especially gut-selective anti-integrin therapy, in a treat-to-target strategy based on clinical evidence and real-world experience.

We believe you will find this symposium provides useful information that you can incorporate into your own approach to managing patients with UC. I, along with my two colleagues, thank you for joining us this evening and hope you enjoy this event.